Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.
AI.gov.au launches to help safe and responsible AI use
Providing guidance, tools and resources to help Australian businesses use AI safely, the...
AusBiotech responds to Budget 2026–27
The life sciences industry body has responded to measures set out in the Australian...
$6.2m for nine science projects involving Japan and neighbours
Investments under the Global Science and Technology Diplomacy Fund will support nine...
